AC-262 (Accadrine) 10mg Capsules

Description

What Is AC-262 (Accadrine)?

AC-262, also referred to as accadrine or AC-262,536, is a non-steroidal selective androgen receptor modulator (SARM) developed by Acadia Pharmaceuticals. AC-262 exhibits approximately 66 percent of the anabolic potency of testosterone with only 27 percent of its androgenic activity, yielding a selectivity ratio that has positioned it as a compound of significant interest in tissue-selective androgen signaling research.

Characterization studies demonstrate that AC-262 binds to the androgen receptor with a Ki of 5 nM, placing its affinity in the same range as established SARMs while offering a milder overall pharmacological profile. Preclinical data in castrated rats showed that AC-262 restored levator ani muscle weight to near-intact levels at doses that produced only marginal increases in prostate weight, confirming robust tissue selectivity. The compound has also demonstrated neuroprotective activity in Alzheimer’s disease models, reducing the effects of DHT-induced androgen receptor degradation and attenuating amyloid-beta accumulation in preliminary cell culture studies.

Key Features and Specifications

Mechanism of Action: How AC-262 Works

AC-262 functions as a partial agonist at the androgen receptor, activating AR-mediated transcriptional programs in skeletal muscle and bone tissue while producing substantially attenuated signaling in prostate and seminal vesicle tissues. The partial agonist mechanism means AC-262 competes with endogenous androgens for receptor binding but generates a submaximal transcriptional response, contributing to its milder overall pharmacological profile compared to full agonist SARMs.

In muscle tissue, AC-262 stimulates the expression of anabolic genes including MyoD, myogenin, and IGF-1, promoting protein synthesis and myofiber hypertrophy. The compound also influences the hypothalamic-pituitary-gonadal axis, with preclinical studies showing reductions in luteinizing hormone at higher doses, indicating dose-dependent suppressive potential that is generally milder than that observed with more potent SARMs such as RAD-140 or LGD-4033.

Neuroprotective research has revealed that AC-262 modulates androgen receptor activity in neuronal tissue, potentially protecting against neurodegenerative processes. These findings, while preliminary, have opened an additional research avenue beyond the traditional muscle and bone applications of SARM compounds.

Reported Research Applications and Benefits

Lean mass research with AC-262 has demonstrated consistent anabolic effects in castrated animal models, with the compound restoring muscle mass at doses that produce minimal androgenic stimulation. The milder profile makes accadrine particularly valuable in studies investigating the lower end of the SARM dose-response curve and in protocols where minimizing hormonal disruption is a design priority.

Neuroprotection studies represent a growing area of AC-262 research. Preliminary data suggest that the compound reduces androgen receptor degradation in neuronal cells exposed to toxic stimuli, and in vitro models of Alzheimer’s disease have shown reductions in amyloid-beta plaque formation with AC-262 treatment. These dual anabolic-neuroprotective properties are unique among characterized SARMs.

Prostate research has leveraged AC-262’s tissue selectivity to investigate partial agonist approaches to androgen receptor modulation that maintain musculoskeletal benefits while sparing prostatic tissue. Comparative SARM studies frequently include AC-262 as a reference compound for evaluating the relationship between binding affinity, agonist efficacy, and tissue selectivity.

AC-262 Dosage Information for Research

AC-262 vs Ostarine: Key Differences

Storage and Handling Instructions

Store AC-262 capsules at controlled room temperature between 20°C and 25°C (68°F to 77°F) in the original sealed container. Protect from light, heat, and moisture. Under recommended storage conditions, AC-262 capsules maintain full potency for at least 24 months from the date of manufacture.

Why Choose PrymaLab AC-262 Accadrine Capsules

Every batch of PrymaLab AC-262 undergoes independent third-party testing by accredited laboratories using HPLC for purity determination and mass spectrometry for identity confirmation. Each order includes a batch-specific Certificate of Analysis documenting ≥99% purity, heavy metal screening, residual solvent analysis, and microbial testing. Pharmaceutical-grade encapsulation ensures precise 10 mg dosing, and free priority shipping is included on all domestic orders.

Frequently Asked Questions About AC-262

What is the primary advantage of AC-262 over more potent SARMs?

AC-262 offers meaningful anabolic activity at approximately 66 percent of testosterone’s potency while producing only 27 percent of its androgenic effects. This favorable selectivity ratio, combined with milder suppression of the HPG axis, makes accadrine well-suited for research protocols where minimizing hormonal disruption is a primary design consideration.

Does AC-262 have neuroprotective properties?

Preliminary research suggests AC-262 protects neuronal cells against androgen receptor degradation and reduces amyloid-beta accumulation in cell culture models relevant to Alzheimer’s disease. These neuroprotective effects, while requiring further validation, represent a unique research avenue not commonly associated with other SARM compounds.

How does AC-262 compare to RAD-140 in terms of potency?

RAD-140 exhibits substantially higher anabolic potency with a 90:1 anabolic-to-androgenic ratio and stronger AR binding affinity compared to AC-262. However, AC-262 produces milder hormonal suppression and a more conservative overall pharmacological profile, making it more appropriate for research designs requiring lower-intensity androgen receptor modulation.

Does AC-262 require post-cycle therapy?

At lower research doses of 10 mg per day, AC-262 generally produces minimal HPG axis suppression. Higher doses and longer durations may warrant PCT considerations. Baseline and endpoint hormone panels are recommended in all research protocols to objectively assess suppression and guide recovery strategies.

What purity should researchers expect from AC-262?

Research-grade AC-262 should test at ≥99% purity by HPLC. PrymaLab provides batch-specific Certificates of Analysis with every order, documenting purity, identity, and comprehensive contaminant screening performed by independent accredited laboratories.

Quality Assurance and Testing

PrymaLab maintains pharmaceutical research-grade quality standards for all AC-262 products. Each batch is independently tested using HPLC purity analysis, mass spectrometry identity verification, heavy metal screening, residual solvent testing, and microbial assessment. Batch-specific Certificates of Analysis accompany every order for full analytical transparency.

Research Disclaimer

AC-262 (accadrine) is sold strictly for laboratory research and scientific investigation purposes only. This product is not intended for human consumption, veterinary use, or therapeutic application. AC-262 has not been approved by the FDA or any regulatory agency for medical use. Purchasers must be qualified researchers affiliated with accredited institutions or licensed research organizations. By purchasing this product, you confirm that it will be used exclusively in accordance with all applicable local, state, and federal regulations governing research materials.